Claims for Patent: 12,310,978

Summary for Patent: 12,310,978

Title:	Composition and method for oral delivery of androgen prodrugs
Abstract:	Provided oral testosterone undecanoate compositions can be administered to hypogonadal males with a meal without the fat content of the meal substantially effecting bioavailability.
Inventor(s):	Mahesh V. Patel, Nachiappan Chidambaram, Satish K. Nachaegari
Assignee:	Lipocine Inc
Application Number:	US16/726,572
Patent Claims:	1. A method for replacement therapy in a male for a condition associated with a deficiency or absence of endogenous testosterone, said method comprising: orally administering to a male having a condition associated with a deficiency or absence of endogenous testosterone, with a meal having a fat content of a predetermined amount, a pharmaceutical composition comprising from about 50 mg to about 300 mg of testosterone undecanoate and a pharmaceutically acceptable carrier, wherein said administration of said pharmaceutical composition provides bioequivalent amounts of serum testosterone, testosterone undecanoate, dihydrotestosterone, or dihydrotestosterone undecanoate levels to said male regardless of the amount of said fat content of said meal. 2. The method of claim 1, wherein said pharmaceutical composition has about 75 mg, about 112.5 mg, about 150 mg, about 225 mg, or 300 mg of testosterone undecanoate. 3. The method of claim 1, wherein said predetermined amount of fat content of said meal comprises at least one of a high fat content, a standard fat content, and a low fat content. 4. The method of claim 1, wherein said method provides a serum testosterone Cavg in the range of 300 ng/dL to 1100 ng/dL. 5. The method of claim 1, wherein said administering occurs twice-a-day. 6. The method of claim 1, wherein said method comprises administering from 285 mg to about 625 mg of testosterone undecanoate per day. 7. The method of claim 1, wherein said composition comprises a lipophilic additive. 8. The method of claim 1, wherein said composition comprises a hydrophilic additive. 9. The method of claim 1, wherein said pharmaceutical composition (1) is pharmaceutically equivalent to an oral pharmaceutical composition having about 75 mg or about 112.5 mg of testosterone undecanoate at about 15 wt % loading, about 63 wt % glyceryl monolinoleate, about 16 wt % polyoxyl 40 hydrogenated castor oil, and about 6 wt % PEG 8000 or (2) has about 75 mg or about 112.5 mg of testosterone undecanoate at about 15 wt % loading, about 63 wt % glyceryl monolinoleate, about 16 wt % polyoxyl 40 hydrogenated castor oil, and about 6 wt % PEG 8000. 10. The method of claim 1, wherein said method comprises administering the pharmaceutical composition as 2, 3, 4, 5, 6, 7, or 8 unit dosage forms per day. 11. A method for replacement therapy in a male for conditions associated with a deficiency or absence of endogenous testosterone, said method comprising: orally administering to a male having a condition associated with a deficiency or absence of endogenous testosterone, with a meal having about 10 wt % to 50 wt % fat, a pharmaceutical composition comprising from about 50 mg to about 300 mg of testosterone undecanoate and a pharmaceutically acceptable carrier, wherein said pharmaceutical composition provides bioequivalent amounts of serum testosterone, testosterone undecanoate, dihydrotestosterone, or dihydrotestosterone undecanoate levels to said male regardless of the wt % fat of said meal. 12. The method of claim 11, wherein said pharmaceutical composition (1) is pharmaceutically equivalent to an oral pharmaceutical composition having about 75 mg or about 112.5 mg of testosterone undecanoate at about 15 wt % loading, about 63 wt % glyceryl monolinoleate, about 16 wt % polyoxyl 40 hydrogenated castor oil, and about 6 wt % PEG 8000 or (2) has about 75 mg or about 112.5 mg of testosterone undecanoate at about 15 wt % loading, about 63 wt % glyceryl monolinoleate, about 16 wt % polyoxyl 40 hydrogenated castor oil, and about 6 wt % PEG 8000. 13. The method of claim 11, wherein said method provides a serum testosterone Cavg in the range of 300 ng/dl to 1100 ng/dL. 14. The method of claim 11, wherein said method comprises administering from 285 mg to about 625 mg of testosterone undecanoate per day. 15. The method of claim 11, said administering occurs twice-a-day. 16. The method of claim 1, wherein said pharmaceutical composition has about 75 mg, about 112.5 mg, about 150 mg, about 225 mg, or 300 mg of testosterone undecanoate, and wherein said pharmaceutically acceptable carrier is selected to provide bioequivalent amounts of serum testosterone levels to said male for meals containing low fat, standard fat and high fat, and wherein said method provides a serum testosterone Cavg in the range of 300 ng/dl to 1100 ng/dL, and wherein said administering occurs twice-a-day, and wherein said method comprises administering from 285 mg to about 625 mg of testosterone undecanoate per day. 17. The method of claim 16, wherein said composition comprises a lipophilic additive and a hydrophilic additive. 18. The method of claim 16, wherein said pharmaceutical composition (1) is pharmaceutically equivalent to an oral pharmaceutical composition having about 75 mg or about 112.5 mg of testosterone undecanoate at about 15 wt % loading, about 63 wt % glyceryl monolinoleate, about 16 wt % polyoxyl 40 hydrogenated castor oil, and about 6 wt % PEG 8000 or (2) has about 75 mg or about 112.5 mg of testosterone undecanoate at about 15 wt % loading, about 63 wt % glyceryl monolinoleate, about 16 wt % polyoxyl 40 hydrogenated castor oil, and about 6 wt % PEG 8000. 19. The method of claim 16, wherein said method comprises administering the pharmaceutical composition as 2, 3, 4, 5, 6, 7, or 8 unit dosage forms per day. 20. A method for replacement therapy in a male for a condition associated with a deficiency or absence of endogenous testosterone, said method comprising: orally administering to a male having a condition associated with a deficiency or absence of endogenous testosterone, with a meal, a pharmaceutical composition comprising testosterone undecanoate and a pharmaceutically acceptable carrier, wherein said pharmaceutical composition provides bioequivalent amounts of serum testosterone, testosterone undecanoate, dihydrotestosterone, or dihydrotestosterone undecanoate levels to said male when administered with meals containing at least one of standard fat, low fat, and high fat, wherein said method provides a serum testosterone Cavg in the range of 300 ng/dl to 1100 ng/dL, and wherein said administering occurs twice-a-day, and wherein said method comprises administering from 285 mg to about 625 mg of testosterone undecanoate per day, and wherein said composition comprises a lipophilic additive and a hydrophilic additive, and wherein said method comprises administering the pharmaceutical composition as 2, 3, 4, 5, 6, 7, or 8 unit dosage forms per day.